Next-generation Cologuard exhibited improved colorectal cancer specificity and sensitivity compared with results of the FDA registrational trial that led to approval of the noninvasive screening test, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Universal Diagnostics (Universal DX), a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, today announced the results ...

WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...

A next-generation multitarget stool DNA test, including assessments of DNA molecular markers and hemoglobin level, was developed to improve the performance of colorectal cancer screening, primarily ...